Lack of Updates Resverlogix and ZenithWell we know that Resverlogix has been visible in January and February at key conferences and has given presentations. March will be very busy with 5 events planned and we know Dr Wong will be presenting at at least 1 event to promote BETonMACE. So that's good.
As a side point I found an excellent summary of the ASSURE and SUSTAIN trials at
https://www.resverlogix.com/programs/clinical-cardiovascular-program/rvx-208-clinical-program/rvx-208-clinical-development.html#.VO3goShy9SU It is a very brief and clear summary and gives me great reassurance about the potential of rvx-208. It shows that multiple secondary IVUS endpoints, very important markers, that were achieved at highly statistically significant levels. Again reinforcing why Eastern Capital and NGN Capital are holding steady in terms of share ownership and providing financing.
Hopefully we'll get a concrete update on the trial very soon. We all know that RVX are very poor communicators but at least they seem to be keeping the website somewhat up tp date and apparently there is a blog.
However, at Zenith it seems like a completely different story. I checked their website and I can't find any future activity. Perhaps I missed it but it sure isn't obvious that they are doing anything at all. It seems like ever since abandoned ZEN3365 everything has gone dead. When Zenith was formed it could have been done for 1 or both of 2 reasons;
- The belief that the SUSTAIN trial would achieve it's primary end point of -0.6% change in PAV and this would drive the value of RVX through the roof in terms of share price. (It turned do out that -0.4 PAV reduction was achieved (p=.08).)
- The belief in the potential of the Zenith portfolio of epigenetic processes and compounds in terms of developing an entirely new business or businesses producing compounds to deal with various diseases including certain types of cancers and many other disease resulting from inflammation and other causes.
So my (probably naive) belief was that Zenith was probably far enough along in it's patents and epigenetic knowledge that an IPO would be launched shortly after it was created in the spring of 2013. Well I was wrong.
Now, in the absence of any communications or statement of direction I'm beginning to wonder if there is anything of substance at Zenith? Of cousre there must be value there otherwise they could not have attracted Dr Cheerrington to join the company and they would not have set up an office in Sanfran Cisco. There must be reasons for the silence such as;
- Dr Cherrington is "kicking the tires" to see what is there and then developing a strategy?
- They are back in the lab testing the ZEN3365 replacement?
- They are seeking a strategic partner to carry them to the next level?
- They are in the processes of constructing an IPO to raise financing?
- Etc.
Anyway, I intended a short post to ask if anyone has any more information on either company at this stage.
GLTA
Cheers
Toinv :)